Equities analysts expect Krystal Biotech Inc (NASDAQ:KRYS) to report earnings per share (EPS) of ($0.31) for the current quarter, Zacks reports. Zero analysts have made estimates for Krystal Biotech’s earnings. The lowest EPS estimate is ($0.33) and the highest is ($0.29). Krystal Biotech reported earnings of ($0.22) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 40.9%. The firm is scheduled to issue its next quarterly earnings report on Monday, August 5th.
On average, analysts expect that Krystal Biotech will report full-year earnings of ($1.42) per share for the current fiscal year, with EPS estimates ranging from ($1.69) to ($1.18). For the next fiscal year, analysts forecast that the company will report earnings of ($1.55) per share, with EPS estimates ranging from ($1.83) to ($1.14). Zacks’ EPS calculations are an average based on a survey of research analysts that cover Krystal Biotech.
Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Tuesday, May 7th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.04.
A number of research firms have recently commented on KRYS. Zacks Investment Research raised shares of Krystal Biotech from a “sell” rating to a “hold” rating in a research report on Wednesday, April 10th. Guggenheim initiated coverage on shares of Krystal Biotech in a research note on Thursday, May 30th. They set a “buy” rating and a $31.57 price target on the stock. Cowen reiterated a “buy” rating on shares of Krystal Biotech in a research note on Monday, May 6th. ValuEngine upgraded shares of Krystal Biotech from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. Finally, Chardan Capital boosted their target price on shares of Krystal Biotech from $50.00 to $57.50 and gave the company a “buy” rating in a research note on Tuesday, March 12th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $37.01.
KRYS stock opened at $32.08 on Monday. The company has a market cap of $457.57 million, a P/E ratio of -33.07 and a beta of 0.73. The company has a quick ratio of 33.28, a current ratio of 33.28 and a debt-to-equity ratio of 0.03. Krystal Biotech has a 52 week low of $13.25 and a 52 week high of $38.95.
Several institutional investors and hedge funds have recently added to or reduced their stakes in KRYS. Great Point Partners LLC acquired a new stake in Krystal Biotech in the fourth quarter valued at about $10,226,000. FMR LLC increased its holdings in Krystal Biotech by 32.1% in the fourth quarter. FMR LLC now owns 1,235,400 shares of the company’s stock worth $25,672,000 after purchasing an additional 300,000 shares in the last quarter. Frazier Management LLC increased its holdings in Krystal Biotech by 40.0% in the fourth quarter. Frazier Management LLC now owns 875,000 shares of the company’s stock worth $18,183,000 after purchasing an additional 250,000 shares in the last quarter. Sphera Funds Management LTD. bought a new stake in Krystal Biotech in the fourth quarter worth approximately $3,629,000. Finally, Artal Group S.A. boosted its position in shares of Krystal Biotech by 83.3% during the fourth quarter. Artal Group S.A. now owns 275,000 shares of the company’s stock valued at $5,715,000 after buying an additional 125,000 shares during the last quarter. 46.05% of the stock is currently owned by institutional investors.
About Krystal Biotech
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease.
Further Reading: What is the yield curve?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.